Wedbush Reaffirms “Outperform” Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “outperform” rating reiterated by Wedbush in a report released on Thursday, RTT News reports. They presently have a $84.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 24.35% from the stock’s previous close. Wedbush also issued estimates for Keros Therapeutics’ Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Other analysts have also recently issued reports about the company. Jefferies Financial Group began coverage on Keros Therapeutics in a research note on Tuesday. They issued a “buy” rating on the stock. Guggenheim started coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Cantor Fitzgerald began coverage on Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday. Finally, Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Performance

NASDAQ:KROS traded up $1.10 during trading hours on Thursday, reaching $67.55. The company’s stock had a trading volume of 77,517 shares, compared to its average volume of 368,025. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -13.14 and a beta of 1.23. The firm has a 50-day simple moving average of $56.87 and a 200-day simple moving average of $51.89. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm had revenue of $0.39 million during the quarter. During the same quarter last year, the company earned ($1.33) EPS. The business’s revenue was up 4750.0% on a year-over-year basis. Equities analysts anticipate that Keros Therapeutics will post -4.9 earnings per share for the current fiscal year.

Insider Transactions at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares in the company, valued at $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after acquiring an additional 251 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Keros Therapeutics by 25.5% during the 1st quarter. GSA Capital Partners LLP now owns 8,538 shares of the company’s stock valued at $565,000 after buying an additional 1,736 shares during the period. Swiss National Bank boosted its stake in shares of Keros Therapeutics by 22.0% in the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $3,303,000 after buying an additional 9,000 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Keros Therapeutics by 26.5% in the first quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock worth $472,000 after acquiring an additional 1,496 shares during the period. Finally, Vanguard Group Inc. increased its position in Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after acquiring an additional 113,563 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.